#CRPC Epidemiology

[stevenwilliam12]

CRPC Market Size, Growth Analysis, and Epidemiological Forecast 2032  

Castrate-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that continues to progress despite androgen deprivation therapy (ADT), which lowers testosterone to castrate levels. This condition presents significant challenges due to its resistance to standard hormonal treatments, making it a focal point for new research and therapies. This article explores the epidemiology of CRPC, key market insights, and a forecast of the global market through 2032.

Epidemiology of Castrate-Resistant Prostate Cancer

Prostate cancer remains one of the most common malignancies affecting men globally. According to the World Health Organization (WHO), prostate cancer accounted for over 1.4 million cases worldwide in 2020, with a notable percentage developing into CRPC.

Incidence and Prevalence: Roughly 20-30% of prostate cancer cases progress to castrate-resistant stages. CRPC tends to manifest in patients who have undergone several rounds of hormone therapy and is more common in men over the age of 65. Other contributing risk factors include family history and genetic predisposition.

Regional Differences: CRPC prevalence varies across regions. North America and Europe report higher rates due to their aging populations and improved diagnostic capabilities. Meanwhile, lower incidence rates are found in Asia and Africa, though increasing awareness is closing this gap.

Key Insights into the CRPC Market

Advances in Early Diagnosis: Improved awareness of prostate cancer and enhanced diagnostic technologies have contributed to earlier detection of CRPC. Biomarkers such as prostate-specific antigen (PSA) and advanced imaging techniques are crucial in diagnosing and monitoring the progression of the disease.

Innovation in Treatment Options: The CRPC treatment landscape has evolved with the development of novel therapies such as androgen receptor inhibitors, immunotherapies, and targeted radiotherapies. Medications like enzalutamide, abiraterone acetate, and newer therapies have significantly enhanced the management of CRPC, driving market growth.

Cost of Treatment: CRPC treatments are often expensive, limiting access to cutting-edge therapies, particularly in regions with less-developed healthcare systems. However, the emergence of more treatment options is expected to broaden availability and improve affordability over time.

Rise in Clinical Trials: A robust pipeline of clinical trials focusing on CRPC therapies has emerged, with numerous studies underway to explore more effective treatments. These efforts aim to improve survival rates and provide better patient outcomes, potentially leading to a more competitive market with a variety of options.

Market Forecast Through 2032

The global CRPC market is expected to experience significant growth over the next decade. Several factors will contribute to this upward trajectory:

Increasing Incidence: With an aging global population and improved diagnostic measures, the incidence of CRPC is set to rise, driving demand for more advanced and effective treatment options.

Research and Development: Ongoing R&D efforts, focusing on developing new therapeutic approaches, will likely accelerate the market. Breakthroughs in immunotherapy, precision medicine, and combination therapies are expected to shape the future of CRPC treatment.

Projected Market Growth: Analysts predict that the CRPC market could grow at a compound annual growth rate (CAGR) of XX% over the forecast period, reaching an estimated value of USD XX billion by 2032. The market’s expansion will be driven by advancements in drug development, the increasing prevalence of the disease, and the rising healthcare expenditure worldwide.

Conclusion

The castrate-resistant prostate cancer market is projected to grow significantly in the coming years, propelled by increased awareness, better diagnostic techniques, and innovative therapies. However, addressing challenges like the high cost of treatment and improving access to these therapies globally will be essential. The market outlook for 2032 is positive, with ongoing research and new treatment options poised to enhance patient outcomes and the overall management of CRPC.

Related Reports Offered By DelveInsight:

Prostate Cancer Market

DelveInsight’s “Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of all prostate cancer types, historical and forecasted epidemiology as well as the prostate cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market

DelveInsight’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the metastatic prostate cancer, historical and forecasted epidemiology as well as the metastatic prostate cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market

DelveInsight’s “Metastatic Castration-Sensitive Prostate Cancer Market Insight, Epidemiology and Market Forecast – 2034” report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM mCSPC market size from 2020 to 2034. The report also covers current mCSPC treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

Metastatic Prostate Cancer Market

DelveInsight’s “Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the metastatic prostate cancer, historical and forecasted epidemiology as well as the metastatic prostate cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Non-metastatic Prostate Cancer (nmPC) Market

DelveInsight’s “Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the metastatic prostate cancer, historical and forecasted epidemiology as well as the metastatic prostate cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Prostate Cancer Diagnostics Market

Prostate Cancer Diagnostics Market By Test Type (Imaging Tests, Biomarker Tests, Biopsy, Immunohistochemistry, And Others), End-User (Hospitals & Clinics, Diagnostic Centers, Research & Academics, And Others), And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) is expected to grow at a steady CAGR forecast till 2030 owing to the rising incidence of prostate cancer and increasing awareness and screening programs.

Prostate Cancer Market Prostate Cancer Market By Product Type (Diagnosis [Blood Test, Imaging Test, Biopsy, And Others] And Treatment [Therapeutics {Chemotherapy, Hormonal Therapy, And Others}, Radiation Therapy, Surgery, And Others]), End-User (Hospitals, Speciality Clinics, Diagnostic Centers, And Others), And By Geography Is Expected To Grow At A Steady Cagr Forecast Till 2030 Owing To The Rising Incidence For Prostate Cancer And Growing Awareness On Prostate Cancer Among Men.

[editorspride]

Castrate-resistant Prostate Cancer (CRPC) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

http://dlvr.it/RcYQBn

[universalnewspoint]

Castrate-resistant Prostate Cancer (CRPC) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

http://dlvr.it/RcYPGX

[conversationpoint]

Castrate-resistant Prostate Cancer (CRPC) Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

http://dlvr.it/RcYLSM

[sandlerresearch]

Prostate Cancer: Global Drug Forecast and Market Analysis to 2028 published on

http://www.sandlerresearch.org/prostate-cancer-global-drug-forecast-and-market-analysis-to-2028.html

Prostate Cancer: Global Drug Forecast and Market Analysis to 2028

Prostate Cancer: Global Drug Forecast and Market Analysis to 2028

Summary

The prostate cancer market in the 8 major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China) is expected to experience a moderate growth between 2018 and 2018. The main drivers of growth will be an aging population, continued uptake of second-generation hormonal agents in the metastatic hormone naïve (mHNPC) and non-metastatic castration resistant (nmCRPC) prostate cancer settings, and the launch and uptake of 13 new premium-priced therapies, including the newly approved Nubeqa (darolutamide).

Until recently, the hormone sensitive setting has been dominated by the use of cheaper first-generation hormonal agents, with the use of premium-priced second-generation hormonal agents (Xtandi and Zytiga) limited to metastatic CRPC. The prostate cancer competitive landscape is experiencing a substantial change. Given that Zytiga and Xtandi are limited by the insurgence of acquired resistance, physicians will face the critical issue of determining the best treatment sequence for subsequent lines of therapy, most notably in the mCRPC setting. Additionally, companies are now moving toward a more personalized approach in prostate cancer, targeting mCRPC patients with specific genetic signatures, such as PTEN loss and DNA repair abnormalities. GlobalData expects these biomarker-driven drug development strategies to induce further patient stratification and to add complexity to the CRPC treatment algorithm.

Key Highlights

– The main driver of the growth of the prostate cancer market will be the continued uptake of second-generation hormonal agents into mHNPC and nmCRPC, where the extended treatment duration will drive overall sales. The second strongest driver will be the increasing number of incident cases. – To gain approval and obtain reimbursement, it is essential for pipeline drugs to demonstrate greater efficacy (overall survival) compared with available agents. For this reason, agents positioned as first-line mCRPC treatments are being investigated in combination with second-generation hormonal agents, the current standard of care (SOC), to limit the “standard-of-care hurdle”. The earlier use of these agents in the hormone-sensitive disease may negatively affect the uptake of this combination in the later line of treatment, mCRPC. – Due to concerns related to the high annual cost of therapy, GlobalData expects heavy generic erosion of Zytiga when abiraterone generics launch, starting in 2018.

Scope

– Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. – Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2018 to 2028. – Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market. – Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled. – Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to – – Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global prostate cancer market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global prostate cancer market in the future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

[sandlerresearch]

Prostate Cancer: Epidemiology Forecast to 2028 published on

http://www.sandlerresearch.org/prostate-cancer-epidemiology-forecast-to-2028.html

Prostate Cancer: Epidemiology Forecast to 2028

Prostate Cancer: Epidemiology Forecast to 2028

Summary

Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.2 million men were diagnosed with prostate cancer in 2018 (International Agency for Research on Cancer, 2019). Almost all prostate cancers are adenocarcinomas, a type of cancer that develops in gland cells. Most prostate cancers are asymptomatic and grow very slowly. In advanced stages of prostate cancer, the malignancy has spread to other organs such as seminal vesicles, lymph nodes, or bones. When a tumor fails to respond to androgen deprivation therapy, it is referred to as castration-resistant prostate cancer (CRPC) (National Cancer Institute, 2019a). Changes in PSA testing and screening guidelines since 2007 have led to substantial changes in prostate cancer incidence. GlobalData epidemiologists used the most recent data for incidence calculations in the 8MM.

In 2018, the US accounted for 30.46% of the diagnosed incident cases of prostate cancer in the 8MM, with 170,744 cases. There were 216,980 cases in the 5EU in 2018, or 38.71% of the diagnosed incident cases, while Japan had 93,916 diagnosed incident cases and China had 78,874 diagnosed incident cases. In the 8MM, the number of diagnosed incident cases of prostate cancer will grow by 19.41% over the forecast period at an Annual Growth Rate (AGR) of 1.94% from 560,514 cases in 2018 to 669,284 cases by 2028. Of the 8MM, the US is expected to have the highest number of diagnosed incident cases, increasing from 170,744 cases in 2018 to 204,127 cases in 2028. Italy had the lowest number of diagnosed incident cases of prostate cancer in 2018, at 35,300 cases. Any change in the diagnosed incident cases of prostate cancer in the 8MM is attributable to changing population demographics in the respective markets.

Scope

– The Prostate Cancer Epidemiology Report and Model provide an overview of the risk factors and global trends of prostate cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). – This report includes 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men segmented by age (beginning at 30 years), Gleason scores (2-10), stage at diagnosis (stage I, II, III, IV-M0, and IV-M1), risk category (very low/low risk, intermediate risk, and high/very high risk), and metastatic cases at diagnosis (bone metastases only and bone metastases with visceral metastases) in these markets. Additionally, this report forecasts five-year diagnosed prevalent cases of prostate cancer segmented by castration resistance and metastases. – The prostate cancer epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists. – The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM. – The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The Prostate Cancer Epidemiology series will allow you to – – Develop business strategies by understanding the trends shaping and driving the global prostate cancer market. – Quantify patient populations in the global prostate cancer market to improve product design, pricing, and launch plans. – Organize sales and marketing efforts by identifying the age groups that present the best opportunities for prostate cancer therapeutics in each of the markets covered. – Understand magnitude of prostate cancer by stage at diagnosis and risk category.